Cannabinoid Agonist Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

(Albany, US) On October 28, 2026 – DelveInsight’s, “Cannabinoid Agonist Pipeline Insight 2026” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Cannabinoid Agonist pipeline landscape. It covers the Cannabinoid Agonist pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cannabinoid Agonist pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Cannabinoid Agonist Pipeline @ https://www.delveinsight.com/sample-request/cannabinoid-agonist-pipeline-insight

Key Takeaways from the Cannabinoid Agonist Pipeline Report

• On October 22, 2026 – MIRA Pharmaceuticals reported positive preclinical results for MIRA-55 in chronic inflammatory pain. The company reported sustained pain-relieving activity in a preclinical model and is advancing MIRA-55, an oral synthetic cannabinoid analog, toward a planned Investigational New Drug (IND) submission in the first quarter of 2027. The candidate remains in preclinical development, and its safety and efficacy in humans have not been established.
• On October 05, 2026 – Endovia Health Sciences and Lupvindol BioSciences announced an FDA regulatory milestone for CannEpil. The FDA determined that the investigational CBD-THC oral solution for canine bone cancer pain qualifies as a minor use, making it eligible to pursue a conditional approval pathway. CannEpil remains investigational and has not yet received FDA approval.
• DelveInsight’s Cannabinoid Agonist pipeline report depicts a robust space with 20+ Cannabinoid Agonist companies working to develop 22+ pipeline therapies for Cannabinoid Agonist treatment.
• The leading Cannabinoid Agonist Companies such as Apurano Pharmaceuticals, IGC Pharma, Inc., Artelo Biosciences, Inc., NeuroTherapia, Oxford Cannabinoid Technologies Holdings, SciSparc, Mira Pharmaceuticals, InMed Pharmaceuticals, Corbus Pharmaceuticals and others.
• Promising Cannabinoid Agonist Pipeline Therapies such as GW842166, Lenabasum 20 mg, CNTX-6016 and others.

Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Cannabinoid Agonist Treatment Drugs

Cannabinoid Agonist Overview

Cannabinoid agonists are compounds that activate the cannabinoid receptors (CB1 and CB2), which are part of the endocannabinoid system. These agonists can be natural (e.g., tetrahydrocannabinol or THC from cannabis), endogenous (e.g., anandamide), or synthetic (e.g., nabilone). They have diverse therapeutic applications, including pain management, appetite stimulation, anti-inflammatory effects, and neuroprotection. The increasing incidence of chronic pain, cancer, epilepsy, and neurodegenerative diseases has driven the demand for novel therapeutics, including cannabinoid agonists. The structuresof cannabinoid agonists typically feature terpene and phenolic components, which are characteristic of both phytocannabinoids (like THC and CBD) and synthetic cannabinoids (like dronabinol). Endogenous agonists, such as anandamide, have a fatty acid backbone with an amide group and long carbon chains. Phytocannabinoids, like THC, have a benzopyran ring fused with a terpene structure, while synthetic cannabinoids often include modified aromatic rings, providing unique receptor-binding properties. These structural features determine their ability to bind and activate cannabinoid receptors, influencing various physiological processes.

Cannabinoid Agonist Emerging Drugs Profile

• AP-707: Apurano Pharmaceuticals

Adezunap (AP707) is an investigational THC-based cannabinoid formulation developed by Apurano Pharmaceuticals for chronic pain management. Utilizing the proprietary PuranoTec® manufacturing process, Adezunap is presented as an aqueous nanodispersion administered sublingually via a mouth spray, enhancing rapid and effective absorption through the oral mucosa. The formulation’s small particle size (

• IGC-AD1: IGC Pharma, INC

IGC-AD1 is an investigational, proprietary cannabinoid-based product developed by India Globalization Capital (IGC). It is designed to be a CB2 receptor agonist aimed at treating Alzheimer’s disease by modulating inflammation and neuroprotection in the brain. The product works by targeting the endocannabinoid system to help reduce the neuroinflammation associated with Alzheimer’s. IGC-AD1 has shown promise in preclinical studies for improving cognitive function and addressing neurodegenerative processes, with ongoing clinical trials to evaluate its safety and efficacy. Currently, the drug is in the Phase II Alzheimer Disease clinical pipeline.

• NTRX 07: NeuroTherapia

NTRX-07 is an orally available small molecule that targets a key receptor on activated microglia, specialized cells that play an important role in regulating immune system activity in the CNS. The drug reduces inflammation and improves the brain’s ability to form new connections, leading to improved learning and memory. Inflammation in the brain is increasingly recognized as an important factor in many neurological diseases, and NTRX-07 provides a new approach for the treatment of these challenging conditions. NeuroTherapia is initially developing this product for the treatment of Alzheimer’s disease. Currently the drug is in Phase I stage of its development for the treatment of Alzheimer’s disease.

The Cannabinoid Agonist Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Cannabinoid Agonist with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cannabinoid Agonist Treatment.
• Cannabinoid Agonist Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Cannabinoid Agonist Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cannabinoid Agonist market

Explore groundbreaking therapies and clinical trials in the Cannabinoid Agonist Pipeline @ New Cannabinoid Agonist Drugs

Cannabinoid Agonist Companies

Apurano Pharmaceuticals, IGC Pharma, Inc., Artelo Biosciences, Inc., NeuroTherapia, Oxford Cannabinoid Technologies Holdings, SciSparc, Mira Pharmaceuticals, InMed Pharmaceuticals, Corbus Pharmaceuticals and others.

Cannabinoid Agonist pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Cannabinoid Agonist Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Cannabinoid Agonist Market Drivers and Barriers

Scope of the Cannabinoid Agonist Pipeline Report

• Coverage- Global
• Cannabinoid Agonist Companies- Apurano Pharmaceuticals, IGC Pharma, Inc., Artelo Biosciences, Inc., NeuroTherapia, Oxford Cannabinoid Technologies Holdings, SciSparc, Mira Pharmaceuticals, InMed Pharmaceuticals, Corbus Pharmaceuticals and others.
• Cannabinoid Agonist Pipeline Therapies- GW842166, Lenabasum 20 mg, CNTX-6016 and others.
• Cannabinoid Agonist Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Cannabinoid Agonist Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Cannabinoid Agonist Therapies and clinical trials @ Cannabinoid Agonist Companies, Key Products and Unmet Needs

Table of Contents

1. Report Introduction
2. Cannabinoid Agonist
3. Cannabinoid Agonist – DelveInsight’s Analytical Perspective
4. Therapeutic Assessment
5. Late Stage Products (Phase-III)
6. Mid Stage Products (Phase-II)
7. Early Stage Products (Phase-I)
8. Pre-clinical Products and Discovery Stage Products
9. Inactive Products
10. Dormant Products
11. Discontinued Products
12. Cannabinoid Agonist Product Profiles
13. Cannabinoid Agonist Key Companies
14. Cannabinoid Agonist Key Products
15. Dormant and Discontinued Products
16. Cannabinoid Agonist – Unmet Needs
17. Cannabinoid Agonist – Future Perspectives
18. Cannabinoid Agonist Analyst Review
19. Appendix
20. Report Methodology

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/cannabinoid-agonist-pipeline-insight